Protalix Biotherapeutics (NYSEAMERICAN:PLX) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Saturday.

Other research analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Protalix Biotherapeutics in a research note on Thursday, November 9th. Zacks Investment Research upgraded Protalix Biotherapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Tuesday, October 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Shares of Protalix Biotherapeutics (PLX) traded down $0.02 during midday trading on Friday, reaching $0.69. The company’s stock had a trading volume of 496,760 shares, compared to its average volume of 1,170,000. Protalix Biotherapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.51.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The firm had revenue of $7.53 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period last year, the firm posted ($0.07) EPS.

A number of hedge funds have recently made changes to their positions in the stock. OxFORD Asset Management LLP purchased a new position in Protalix Biotherapeutics during the second quarter valued at approximately $576,000. Virtu KCG Holdings LLC purchased a new position in Protalix Biotherapeutics during the second quarter valued at approximately $591,000. Finally, Renaissance Technologies LLC raised its position in Protalix Biotherapeutics by 302.1% during the first quarter. Renaissance Technologies LLC now owns 1,927,500 shares of the company’s stock valued at $2,621,000 after acquiring an additional 1,448,200 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “Protalix Biotherapeutics (PLX) Lowered to “Strong Sell” at BidaskClub” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/12/02/protalix-biotherapeutics-plx-lowered-to-strong-sell-at-bidaskclub.html.

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.